Compare CDP & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | ICUI |
|---|---|---|
| Founded | 1988 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | N/A | 1992 |
| Metric | CDP | ICUI |
|---|---|---|
| Price | $29.08 | $142.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $33.29 | ★ $183.60 |
| AVG Volume (30 Days) | ★ 909.1K | 285.1K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | ★ 9.45 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $752,757,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $22.03 | ★ N/A |
| Revenue Growth | ★ 0.43 | N/A |
| 52 Week Low | $23.92 | $107.00 |
| 52 Week High | $33.49 | $175.51 |
| Indicator | CDP | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 56.22 |
| Support Level | $29.59 | $143.41 |
| Resistance Level | $30.99 | $150.38 |
| Average True Range (ATR) | 0.60 | 5.09 |
| MACD | -0.09 | -0.58 |
| Stochastic Oscillator | 26.65 | 45.85 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.